Supply chain report: make CMO agreements public, but ‘glib’ onshoring not the answer
A new report commissioned by the US Congress recommends that the FDA should make drug supply chain information public.
By
A new report commissioned by the US Congress recommends that the FDA should make drug supply chain information public.
ByA $1 million price point is not out of question for bluebird bio’s beta thalassemia therapy if long-term benefits are…
ByCongress has renewed its longstanding push for insulin pricing reform with the Affordable Insulin Now Act, but will it be…
ByAn e-commerce drug delivery approach could put a dent in upward spiraling insulin prices, but uptake challenges loom large.
ByOn Rare Disease Day, Pharmaceutical Technology explores how specialty pharmacies and value-based contracts could shape drug distribution.
ByThe pharma industry needs to target its entire value chain if it wants to make a real dent in reducing…
BySome economists state that the Omicron outbreak has sparked a de facto lockdown in New South Wales, forcing businesses to…
AI is main investment target, while 3D printing remains a largely untapped area.
By